La cadena de opciones muestra datos clave de las opciones de acciones de Solid Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Solid Biosciences..

Solid Biosciences (NASDAQ:SLDB) Bolsa, Cadena de Opciones

SOLID BIOSCIENCES INC

Solid Biosciences

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

Solid Biosciences Inc

Press Releases

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Health Care

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Markets

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

News

Solid Biosciences to Participate at Upcoming Investor Conferences

Opinion

Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

General

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Small Cap

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences to Present at Upcoming Scientific Meetings

AVAI

HCWB

QURE

ADC Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

enGene Holdings

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

I-MAB

Inhibrx Biosciences

Invivyd

Jade Biosciences

Kamada

Keros Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Monopar Therapeutics

Neurogene

Ocugen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Verastem

XOMA Royalty

Chardan Capital

JP Morgan

Wedbush

Citigroup

HC Wainwright & Co.

Comments

Solid Biosciences

Solid Biosciences (SLDB) Opciones

Solid Biosciences (NASDAQ:SLDB) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL